A股異動 | Q2淨利下滑,萊寶高科跌停創階段新低
萊寶高科(002106.SZ)跌停,報8.05元創階段新低,總市值56.9億元。公司昨日晚間公吿,上半年歸母淨利潤2.11億元,同比上升6.82%;其中第二季度歸母淨利潤9345.21萬元,同比下降46.89%。本報吿期受實現的匯兑收益較上年同期大幅下降、新增控股子公司萊寶顯示的開辦費支出及收到含回購條款的投資款按約定利率計提利息支出等影響,報吿期內管理費用及財務費用支出較上年同期相應增加,從而對公司經營業績帶來一定的不利影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.